Gland Pharma Q4FY26: Revenue up 22% to ₹17,428 crore, PAT surges 97%
Gland Pharma reported Q4 FY26 consolidated revenue of ₹17,428 crore, up 22% YoY. PAT surged 97% to ₹3,667 crore. Full year FY26 revenue grew 14.5% to ₹64,307 crore. The company recommended a final dividend of ₹20 per share.
The substantial increase in revenue and profit, coupled with a recommended dividend, is a material positive development for shareholders and indicates strong company performance.
The company reported significant year-on-year growth in revenue and profit, along with a strong performance in its CDMO business and a recommended dividend, indicating positive financial health and operational success.
Gland Pharma Limited announced its financial results for the fourth quarter and year ended March 31, 2026. The company reported a consolidated revenue of ₹17,428 crore for Q4 FY26, a 22% increase year-on-year. Profit After Tax (PAT) surged by 97% to ₹3,667 crore in the same period.
For the full fiscal year FY26, consolidated revenues grew by 14.5% to ₹64,307 crore. Adjusted EBITDA for the full year increased by 33% to ₹16,826 crore, with an adjusted EBITDA margin of 26%.
The company's CDMO business showed strong performance, contributing 46% of revenues and growing by 36% year-on-year in Q4 FY26. For the full year FY26, the CDMO business grew by 28%.
Gland Pharma's base business also demonstrated robust growth, with Q4 FY26 revenue increasing by 22% year-on-year to ₹12,648 crore. Full year FY26 revenues for the base business grew by 11% to ₹45,613 crore.
The Board of Directors has recommended a final dividend of ₹20 per equity share for FY26, subject to shareholder approval. The company will conduct an Earnings Call on May 15th, 2026, at 6:30 PM IST to discuss the results.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.